AnaptysBio (ANAB)
(Delayed Data from NSDQ)
$23.41 USD
-2.82 (-10.75%)
Updated May 10, 2024 04:00 PM ET
After-Market: $23.43 +0.02 (0.09%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
ANAB 23.41 -2.82(-10.75%)
Will ANAB be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ANAB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ANAB
AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates
Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Tops Revenue Estimates
ANAB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Guardant (GH) Gears Up for Q1 Earnings: Here's What to Expect
Iovance (IOVA) Gears Up for Q1 Earnings: Here's What to Expect
AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Other News for ANAB
Wedbush Reaffirms Their Buy Rating on AnaptysBio (ANAB)
AnaptysBio (ANAB) Receives a Buy from Piper Sandler
Buy Rating Affirmed for AnaptysBio Amidst Promising Pipeline and Strategic Financial Positioning
The Analyst Landscape: 7 Takes On AnaptysBio
Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update